Why Do My CML PCR Results Change When I Feel Fine?
At a Glance
Small changes in CML BCR::ABL1 PCR results are common because of laboratory methods, sample handling, natural biology, and the limits of testing at very low levels. Doctors focus on the trend; a sustained, roughly 10-fold rise or loss of major molecular response needs prompt review.
In this answer
4 sections
When you have chronic myeloid leukemia (CML), your care team monitors your BCR::ABL1 levels using a highly sensitive blood test called PCR (polymerase chain reaction). It is very common for this number to fluctuate slightly from test to test, even when your leukemia is well-controlled. Because a changing number can cause a lot of anxiety, it is helpful to understand why these shifts happen.
Variations happen because of differences in laboratory methods, natural biological changes, and how your blood sample is handled [1][2][3]. While a small, isolated change is often just “noise,” it is important to know the difference between a harmless fluctuation and a true change in your leukemia that requires your doctor’s attention.
What the PCR Test Measures
The PCR test is the most important tool for tracking your CML. It measures the amount of BCR::ABL1 genetic material (RNA) in your blood as a surrogate for how much leukemia is left in your body.
You might wonder why your PCR number can rise even if you feel perfectly fine and your standard Complete Blood Count (CBC) is normal. CML molecular changes occur on a microscopic level long before they cause symptoms or change your CBC [4]. This is why sticking to your PCR testing schedule is critical.
Your results are typically grouped into molecular response milestones [5]:
- Major Molecular Response (MMR): BCR::ABL1 is at or below 0.1% on the International Scale.
- Deep Molecular Response (MR4 and MR4.5): BCR::ABL1 is at or below 0.01% or 0.0032%, respectively.
If your report says the gene was “not detected,” this is excellent news, but it does not mean there are absolutely zero leukemia cells in your body. It simply means the amount of leukemia is lower than what that specific test is sensitive enough to detect [6].
Why Different Laboratories Get Different Results
Even though most labs report results using the International Scale (IS)—a standardized system designed to make tests comparable across clinics—it does not completely eliminate variations [7]. If you switch laboratories, your number might change simply because of the way the new lab runs the test.
- Different control genes: PCR tests compare the BCR::ABL1 leukemia gene against a normal “control gene” (such as ABL1 or GUSB). Different labs use different control genes, which can shift your result, particularly when your leukemia levels are already very low [2].
- Testing equipment and conversion factors: Each lab uses different chemical reagents and machines. To report on the International Scale, they apply a unique “conversion factor” to their raw data. Differences in these factors can lead to slightly different IS numbers [8].
- Transcript variants: Your specific BCR::ABL1 gene has a certain shape (called a transcript, such as e13a2 or e14a2). While your transcript does not change from visit to visit, tests from different labs are sometimes calibrated differently for these specific variants, which can make your result look artificially higher or lower [1].
Why Numbers Fluctuate at the Same Laboratory
Even if you stay with the exact same laboratory and testing method, your BCR::ABL1 numbers can still bounce around from visit to visit.
- Sample quality and processing time: The genetic material measured by the PCR test is very fragile. Your blood sample must be processed within the specific time limits and temperature conditions set by that testing laboratory [9]. The lab will check your control genes to ensure the sample is high enough quality to yield a valid result.
- Assay sensitivity at low levels: When you reach a deep molecular response, the PCR test is searching for a needle in a haystack. At these microscopic levels, tests are naturally subject to statistical “noise,” making results more variable [5][10].
- Biological variation: The amount of RNA each leukemia cell produces can naturally rise and fall over time [3]. However, a substantial or continuous rise is not just biological noise and always requires a clinical review.
- Medications and adherence: Missing doses reduces how well your disease is controlled, and repeated missed doses can lead to drug resistance [11]. Furthermore, some over-the-counter drugs, supplements, or new prescriptions can interfere with how your body absorbs or metabolizes your targeted therapy (TKI) [12].
Making Sense of the Numbers: When to Wait and When to Act
Doctors look at the big picture rather than reacting to a single PCR result. Here is how you and your care team can best monitor your progress:
- Focus on the trend: A single, very small rise is often harmless. Your doctor will likely want to repeat the test (sometimes sooner than your next scheduled visit) to see if the upward trend continues or if it was just a temporary blip [13].
- Know when to contact your team: While small shifts are normal, a confirmed, substantial rise is not. If your results show a roughly 10-fold (1-log) increase, or if you lose your Major Molecular Response (your number rises above 0.1% IS), you need prompt review by your hematology team [5].
- Never adjust your own medication: Do not stop, switch, or double your TKI doses based on a changing number [14].
- Use the same laboratory when possible: Having your PCR tests done at the same laboratory helps remove inter-lab variability [15]. However, do not delay a necessary test just because you cannot get to your usual lab. If you must switch, make sure your doctor has copies of both lab reports.
Common questions in this guide
Why can my CML PCR result differ when it is tested at another laboratory?
Can my CML PCR level rise even if I feel well and my CBC is normal?
What does “BCR::ABL1 not detected” mean on my CML test?
When does a changing CML PCR result need prompt medical review?
Should I always use the same laboratory for CML PCR testing?
Can missed TKI doses or new supplements change my CML PCR result?
One line in your results can change your plan.
A PCR result showing loss of Major Molecular Response needs prompt review by your care team. We check your results against the latest research to help you prepare for what’s next.
Related questions
Show more
Get notified when new evidence is published on Philadelphia-positive myelogenous leukemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Variant-specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia.
Jacobs K, Moerman A, Vandepoele K, et al.
International journal of laboratory hematology 2024; (46(5)):910-917 doi:10.1111/ijlh.14320.
PMID: 38840510 - 2
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
Spiess B, Rinaldetti S, Naumann N, et al.
PloS one 2019; (14(3)):e0214305 doi:10.1371/journal.pone.0214305.
PMID: 30897165 - 3
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.
Pagani IS, Dang P, Kommers IO, et al.
Haematologica 2018; (103(12)):2026-2032 doi:10.3324/haematol.2018.189787.
PMID: 29976745 - 4
Molecular monitoring in CML and the prospects for treatment-free remissions.
Deininger MW
Hematology. American Society of Hematology. Education Program 2015; (2015()):257-63 doi:10.1182/asheducation-2015.1.257.
PMID: 26637731 - 5
Analytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia.
Kim H, Kim DY, Kim H
Practical laboratory medicine 2026; (50()):e00538 doi:10.1016/j.plabm.2026.e00538.
PMID: 42179678 - 6
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Brown JT, Beldorth IJ, Laosinchai-Wolf W, et al.
The Journal of molecular diagnostics : JMD 2019; (21(4)):718-733 doi:10.1016/j.jmoldx.2019.03.002.
PMID: 31026597 - 7
Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.
Scott S, Travis D, Whitby L, et al.
British journal of haematology 2017; (177(3)):414-422 doi:10.1111/bjh.14557.
PMID: 28295199 - 8
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
White HE, Salmon M, Albano F, et al.
Leukemia 2022; (36(7)):1834-1842 doi:10.1038/s41375-022-01607-z.
PMID: 35614319 - 9
Next-generation digital polymerase chain reaction assay for BCR::ABL1 in chronic myeloid leukemia: comprehensive validation for standardized measurable residual disease detection.
Kim YH, Jang MS, Kim SH, et al.
Blood research 2026; (61(1)).
PMID: 42886318 - 10
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
Scott S, Cartwright A, Francis S, et al.
British journal of haematology 2021; (194(1)):53-60 doi:10.1111/bjh.17521.
PMID: 34114218 - 11
Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
Santoleri F, Lasala R, Ranucci E, et al.
Acta haematologica 2016; (136(1)):45-51 doi:10.1159/000444626.
PMID: 27160310 - 12
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S, Vozniak M, Rhodes J, et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018; (24(6)):433-452 doi:10.1177/1078155217710553.
PMID: 28580869 - 13
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Cross NCP, White HE, Evans PAS, et al.
British journal of haematology 2018; (182(6)):777-788 doi:10.1111/bjh.15542.
PMID: 30125955 - 14
Molecular monitoring in chronic myeloid leukemia-how low can you go?
Branford S
Hematology. American Society of Hematology. Education Program 2016; (2016(1)):156-163 doi:10.1182/asheducation-2016.1.156.
PMID: 27913475 - 15
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts.
Smith BM, Brewer D, Druker BJ, Braun TP
Case reports in oncology 2021; (14(3)):1707-1711 doi:10.1159/000520400.
PMID: 35082629
This page explains CML BCR::ABL1 PCR variation for informational purposes only and does not constitute medical advice. Your hematology team should interpret your results and guide any treatment decisions.